Please assess the completion status of the following clinical trial:

Trial Title: DBS of the Habenula for Treatment- Resistant Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women(non-pregnant) aged 18-65 years old;~* DSM-5 diagnosis (assessed by Structured Clinical Interview for DSM-5) of a current major depressive episode(MDE), either nonpsychotic unipolar major depressive disorder (MDD) or bipolar disorder (BD);~* Chronic illness with current MDE ≥ 24 months duration and/or recurrent illness with at least a total of 4 lifetime episodes (including current episode ≥ 12 months) and a minimum of 5 y since the onset of the first depressive episode;~* For subjects with a bipolar disorder: the last manic or hypomanic episode must have been ≥ 24 months before study enrollment and patients must be maintained on a mood stabilizer (e.g. lithium or another mood stabilizer approved for bipolar disorder)~* Treatment resistance defined as Failure of at least 3 adequate treatments from at least two distinctly different classes (SSRI, SNRI, NaSSA, TCA+, lithium-addition) for a period of 6-8 weeks. If diagnosed as bipolar, failure to respond to (or inability to tolerate) a minimum of three treatments approved for bipolar disorder, including lithium and at least one medication FDA-approved for bipolar depression (e.g., olanzapine/fluoxetine combination, quetiapine, lurasidone).~* At least 1 session of ECT, for which the series of ECT was terminated either due to adverse effects or insufficient response (including at least 6 sessions of bilateral ECT). Or unable to recieve ECT.~* Symptom Severity: HAMD-17 total ≥21;~* Stable antidepressant medical regimen for the month preceding surgery;~* Anticipates a stable psychotropic medication regimen in the next 12 months;~* Able and willing to give written informed consent;~* Modified mini-mental state examination (MMSE) score ≥ 27；~Exclusion Criteria:~* Schizophrenia /history of psychosis unrelated to MDD;~* Severe personality disorder (assessed by SCID-II);~* Alcohol or substance abuse/dependence within 6 months, excluding nicotine dependence;~* Current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or had a serious suicide attempt within the last year;~* Neurological disease (e.g., Parkinson's disease)~* Any history of seizure disorder or hemorrhagic stroke;~* Abnormal brain MRI ;~* Previous sterosurgery;~* Any medical contraindication to surgery;~* Does not have adequate family/friend support as determined by psychological screening and/or interview;~* Unable to maintain a stable psychotropic medication regimen in the next 12 months;~* Pregnant or has plans to become pregnant in the next 12 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Deep Brain Stimulation of Bilateral Habenula (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues